| Dr Devinder S Mangat, MD | |
|
133 Barnwood Dr, Edgewood, KY 41017-2500 | |
| (859) 331-9600 | |
| (859) 331-5831 |
| Full Name | Dr Devinder S Mangat |
|---|---|
| Gender | Male |
| Speciality | Plastic Surgery - Plastic Surgery Within The Head And Neck |
| Location | 133 Barnwood Dr, Edgewood, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265450100 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2082S0099X | Plastic Surgery - Plastic Surgery Within The Head And Neck | 17626 (Kentucky) | Primary |
| Entity Name | Holzapfel & Lied Plastic Surgery Center Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730350216 PECOS PAC ID: 0941251458 Enrollment ID: O20051215000608 |
News Archive
ChemGenex Pharmaceuticals Limited announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid.
Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France).
Biogen Idec and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches. As part of this agreement, a sequencing and analysis facility and shared postdoctoral program will be established at Columbia to support collaborative genetics studies.
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Devinder S Mangat, MD 133 Barnwood Dr, Edgewood, KY 41017-2500 Ph: (859) 331-9600 | Dr Devinder S Mangat, MD 133 Barnwood Dr, Edgewood, KY 41017-2500 Ph: (859) 331-9600 |
News Archive
ChemGenex Pharmaceuticals Limited announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid.
Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France).
Biogen Idec and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches. As part of this agreement, a sequencing and analysis facility and shared postdoctoral program will be established at Columbia to support collaborative genetics studies.
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.
› Verified 9 days ago
Dr. Allison M Holzapfel, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 133 Barnwood Dr, Edgewood, KY 41017 Phone: 859-331-9600 Fax: 859-331-5831 | |
Dr. Deborah R. Sillins, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 3005 Dixie Hwy, Suite 240, Edgewood, KY 41017 Phone: 859-341-3309 Fax: 859-578-4642 |